

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Tanya Arenson on 1/12/2011.

The application has been amended as follows:

In the specification, rewrite the claims as follows:

1. A method of inhibiting a Th2 cytokine and inducing a Th1 cytokine comprising administering to a subject an effective amount of an isolated CpG oligonucleotide, wherein said oligonucleotide consists of a sequence selected from the group consisting of sequences set forth in SEQ ID NOS:2-8, wherein the CpG oligonucleotide comprises at least two unmethylated CpG motifs, and wherein said administering results in inhibition of a Th2 cytokine and induction of a Th1 cytokine in said subject.

4. Cancel.

7. A method for stimulating an immune response comprising administering to a subject an effective amount of an isolated CpG oligonucleotide, wherein said oligonucleotide consists of a sequence selected from the group consisting of sequences set forth in SEQ ID NOS:2-8, wherein the CpG oligonucleotide comprises at least two unmethylated CpG motifs, wherein said administering result in stimulation of an immune

Art Unit: 1632

response in said subject, and wherein said immune response is mediated by inhibiting a Th2 cytokine and inducing a Th1 cytokine.

8. Cancel.

11. A method for treating atopic dermatitis associated with an increase in Th2 cytokines and a decrease in Th1 cytokines in a subject comprising administering to a subject with said atopic dermatitis an effective amount of an isolated CpG oligodeoxynucleotide consisting of a sequence selected from the group consisting of sequences set forth in SEQ ID NO:2-8, wherein the CpG oligonucleotide comprises at least two unmethylated CpG motifs, and wherein said administering is correlated with an improvement of symptoms of said atopic dermatitis in said subject.

12. Cancel.

15. Cancel.

16. A composition for treating atopic dermatitis associated with an increase in Th2 cytokines and a decrease in Th1 cytokines comprising an isolated CpG oligonucleotide consisting of a sequence selected from the group consisting of sequences set forth in SEQ ID NO:2-8, wherein said oligonucleotide comprises at least two unmethylated CpG motifs.

22. Cancel.

23. Cancel.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to MARCIA S. NOBLE whose telephone number is (571)272-5545. The examiner can normally be reached on M-F 9 to 5:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Peter Paras can be reached on (571) 272-4517. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Marcia S. Noble
AU 1632

/Thaian N. Ton/
Primary Examiner, Art Unit 1632